Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
List view / Grid view
Filter the results
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
A new monoclonal antibody has been discovered which disassociates bacterial biofilms and stops bacteria from entering into circulation has been tested in mice.
Researchers have used a drug candidate to block a receptor that contributes to the development of autoimmune disease which could be a potential treatment.
Researchers have shown that a monoclonal antibody prevents viruses from fusing with cell membranes to gain entry.
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.